Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Oncology Progress》 2005-01
Add to Favorite Get Latest Update

Phase Ⅰ study of tegafur combined with oxaliplatin in patients with gastro in testinal cancer

Li Yusheng Hu Xingsheng Cui Chengxu Tang Haijian Lü Jianhong Wany Jinwan Cancer Institute & Hospital,CAMS & PUMC,Beijing 100021,China  
Objective To determine the maximum-tolerated dose(MTD)and dose-limiting toxicity(DLT)of tegafur and oxaliplatin in patients with gastrointestinal cancers.Methods Tegafur was given at escalating doses until MTD was determined,from the initial dose of 400mg/m 2 to 800mg/m 2,1100mg/m 2 and 1336mg/m 2 on d1-5,with CF 100mg/m 2 infused over 2 hours followed by tegafur,oxaliplatin 130mg/m 2 d1.Treatment cycle was repeated every 3 weeks.Results 11 patients received tegafur and oxaliplatin for a total of 32 cycles(median 3 cycles).Nausea and vomiting were dose-limiting toxicities.The MTD of tegafur is 1336mg/m 2.Conclusion We recommend tegafur 800-1100mg/m 2 ivgtt d1-5 combine with oxaliplatin 130mg/m 2 ivgtt d1 at a 3-week interval as suitble dosage for Chinese patients with GI cancer at PS 0-2.
【CateGory Index】: R735
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
Chinese Journal Full-text Database 3 Hits
1 Fan Tiansheng,Huang Xin'en,Jiang Wei,Zhu Jinghua,Gao Huihua,Wang Keqiong,Zhang Cuiling (Department of Chematherapy,Jiangsu Provinceal Tumor Hospital,Nanjing 210009,China);The Observation of the Safety and Efficacy of Continuously Infused Tegafur in the Treatment of Gastrointestinal Cancer[J];Journal of Basic and Clinical Oncology;2006-02
2 HA Bin,LIU Jun,LI Bin,et al. (Department of Oncology,The Fourth Hospital of Anshan,Anshan 114034,China);Clinical observation of oxaliplatin combined with leucovorin and 5-Fu in advanced gastric carcinoma[J];Modern Medicine & Health;2008-04
3 ZHU Hui-yan,WANG Ya-nong,CAI Hong,et al.;The Safety Assessment of Tegafur Injection Combined with Chemotherapy for Digestive System Cancers[J];Bulletin of Chinese Cancer;2006-03
Chinese Journal Full-text Database 10 Hits
1 LI Qing1, FENG Feng yi1, HAN Jun2, SUI Guang jie3, ZHU Yan guang4, ZHANG Yang5, ZHANG Zhen hua6, LI Li7, WANG Ping hui8, ZHOU Mei zhen9, ZHANG Ying chao101. Cancer Hospital,Chinese Academy of Medical Sciences,Beijing 100021,P.R.China2. Shanxi Provincial Cancer Hospital,Xian 710061,P.R.China 3. Heilongjiang Provincial Cancer Hospital,Harbin 150040,P.R.China 4. Xijing Hospital of The Fourth Military Medical University,Xian 710032,P.R.China 5. The Second Clinical College of Dalian Medical University,Dalian 110121,P.R.China6. The First Affiliated Hospital of Xian Medical University,Xian 710061,P.R.China 7. The Affiliated Hospital of Shandong Medical University,Jinan 250012,P.R.China8. Cancer Hospital of Hunan Province,Changsha 410006,P.R.China9. Beijing Hospital,Beijing 100078,P.R.China 10. Cancer Hospital of Sichuan Province,Chengdu 610041,P.R.China;Phase Ⅲ Clinical Study of a New Anticancer Drug Atofluding[J];Chinese Journal of Cancer;2002-12
2 Wen Zhang Da-tong Chu Department of Medical Oncology,Cancer Hospital & Institude,CAMS & PUMC,Beijing 100021,P.R.China;Chemotherapy for Brain Metastases[J];Chinese Journal of Neuro-Oncology;2004-03
3 XU Hongxia , NIE Chunlan, HONG Zhuan. Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210009, P.R.China;Combined chemotherapy of weekly paclitaxel and ifosfamide in the treatment of 23 patients with advanced non-small cell lung cancer[J];Chinese Journal of Lung Cancer;2004-02
4 XU Ying, ZHOU Caicun, ZHANG Jie. Department of Oncology, Shanghai Pneumology Hospital, Shanghai 200433, P.R.China;Hydroxycamptothecine and ifosfamide as second-line therapy in non-small cell lung cancer after prior treatment with platinum-based regimens[J];Chinese Journal of Lung Cancer;2005-01
5 LIU Jie,LIU Yan-mei and ZHANG Yong(School of Chemistry and Chemical Engineer,Shanxi University,Taiyuan 030006);Study on electrochemical behaviors and analytical application of doxorubicin hydrochloride at a glassy carbon electrode[J];Chinese Journal of Analysis Laboratory;2008-06
6 XU Xiao-hong, GONG Zhen-xia, ZHANG Xiao-dong (Department of Oncology, Nantong Tumor Hospital, Nantong 226361,China);A Study of Treatment for Toxic Enteroparalysis Relative to Chemotherapy in Tumor Patients[J];Henan Journal of Oncology;2003-05
7 Guo Yanwei 1, Wang Zhiwei 2, Li Rumin 1 (1.Department of Oncology, Affiliated Hospital of Nanyang Health School,Nanyang 473058,China; 2. Department of Oncology, Nanyang No.2 Hospital, Nanyang 473058,China);Clinical Observation of Paclitaxel plus DDP in Treatment of Advanced Breast Cancer[J];Henan Journal of Oncology;2004-04
8 Sun Jiangtao~1,Qiao Zhifen~2,Shao Jinghua~1,Qiao Yanping~1(1.Wendeng Central Hospital,Weihai 264400,China;2.Wendeng Osteopathic Hospital,Weihai 264400,China);The Observation of Effect of Fluorofur(FT-207) plus Cisplatin in Treatment of Recent and/or Metastatic Head and Neck Cancer Patients[J];Journal of Basic and Clinical Oncology;2006-05
9 Hou Liangbao,Jia Qiulong,Liu Yanzhong,Wang Qing,Liang Weihong (Department of Radiation Oncology,the First Rong Kang Hospital Henan Province,Xinxiang 453003,China);A Study of Concurrent Versus Sequential Chemoradiotherapy with Tegafur and Cisplatin for Old Patients with Locally Advanced Esophageal Carcinoma[J];Journal of Basic and Clinical Oncology;2009-01
10 WANG, Fen LIU, Zhong-Fang LIU, Shao-Pu* (School of Chemistry and Chemical Engineering, Southwest China Normal University, Chongqing 400715);Study on the Interaction between Three Anthracycline Anticancer Drugs and Congo Red by Absorption, Fluorescence and Resonance Rayleigh Scattering Spectra[J];Acta Chimica Sinica;2005-21
China Proceedings of conference Full-text Database 1 Hits
1 ;奈达铂加替加氟治疗食管癌临床疗效分析[A];[C];2005
Chinese Journal Full-text Database 1 Hits
1 孙蔚莉,郑秀立,冯继峰;Combined Treatment of Malignant Meningioma[J];Chinese Medicine of Factory and Mine;1996-05
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved